- In March 2025, QIAGEN filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON intellectual property. This legal action underscores QIAGEN's commitment to safeguarding innovations in latent tuberculosis (TB) testing, particularly the QuantiFERON-TB Gold Plus assay, which is pivotal in global TB control efforts
- In October 2024, QIAGEN hosted the Global TB Summit, bringing together over 35 experts to discuss advancements in TB diagnostics and treatment strategies. The summit highlighted the critical role of QuantiFERON-TB Gold Plus in detecting latent TB infections and emphasized the need for renewed global efforts to combat tuberculosis
- In June 2024, the American Academy of Pediatrics updated its guidelines to recommend QuantiFERON-TB Gold Plus for screening at-risk children of all ages for latent tuberculosis infection. This endorsement reflects the test's accuracy and reliability, even in infants and children under 2 years old, and aligns with broader U.S. tuberculosis control strategies
- In February 2024, Clinical Pathology Laboratories (CPL) implemented single-tube collection for QuantiFERON TB Gold Plus testing, effective June 10, 2024. This change streamlines the testing process, enhancing efficiency and patient comfort while maintaining the assay's diagnostic accuracy
